|
US2021096348A1
|
|
Multi-focal structured illumination microscopy systems and methods
|
|
WO2020236925A1
|
|
Mammalian cell for producing modified vaccinia ankara (mva) virus
|
|
WO2020041470A1
|
|
Methods of metabolic regulation of mitochondria for treating neural injury and neurological disorders using dsh inhibitors
|
|
CA3106869A1
|
|
Intraocular delivery of gene therapy expression vectors
|
|
WO2019213020A1
|
|
Use of epithelial membrane protein 2 (emp2) targeting agents in treating lung disorders
|
|
WO2019144077A1
|
|
Methods and compositions for treating genetically linked diseases of the eye
|
|
EP3707160A1
|
|
Chimeric antigen receptors targeting tumor antigens
|
|
EP3704490A1
|
|
Isotopic biomarkers of organic acidemias
|
|
EP3704102A1
|
|
Substituted quinoline analogs as aldehyde dehydrogenase 1a1 (aldh1a1) inhibitors
|
|
US2020255479A1
|
|
Chimeric reporter west nile/dengue viruses and their use
|
|
CN111163801A
|
|
Hepatitis B nanoparticle-based vaccine for influenza virus
|
|
WO2019018629A1
|
|
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
|
WO2018152526A1
|
|
Zika virus vaccines
|
|
WO2018152505A1
|
|
Efficient cell free production of papillomavirus gene transfer vectors
|
|
WO2018152496A1
|
|
Compositions and methods for the diagnosis and treatment of zika virus infection
|
|
US2020249245A1
|
|
Methods for the detection of tau protein aggregates
|
|
WO2018057950A1
|
|
Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
|
|
US2020270636A1
|
|
Closed-ended, linear, duplex adenoassociated virus dna, and uses thereof
|
|
WO2018052549A1
|
|
Zika virus vaccines
|
|
US2019367917A1
|
|
Diagnosing col6-related disorders and methods for treating same
|
